Investigation of preclinical pharmacokinetics of N -demethylsinomenine, a potential novel analgesic candidate, using an UPLC-MS/MS quantification method.

Demethylsinomenine (NDSM), the demethylated metabolite of sinomenine, has exhibited antinociceptive efficacy against various pain models and may become a novel drug candidate for pain management. However, no reported analytical method for quantification of Demethylsinomenine in a biological matrix is currently available, and the pharmacokinetic properties of Demethylsinomenine are unknown. In the present study, an ultra-high performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) method for quantification of Demethylsinomenine in rat plasma was developed and utilized to examine the preclinical pharmacokinetic profiles of Demethylsinomenine. The liquid-liquid extraction using ethyl acetate as the extractant was selected to treat rat plasma samples. The mixture of 25% aqueous phase (0.35% acetic acid-10 mM ammonium acetate buffer) and 75% organic phase (acetonitrile) was chosen as the mobile phases flowing on a ZORBAX C18 column to perform the chromatographic separation. After a 6-min rapid elution, NDSM and its internal standard (IS), metronidazole, were separated successfully. The ion pairs of 316/239 and 172/128 were captured for detecting Demethylsinomenine and IS, respectively, using multiple reaction monitoring (MRM) under a positive electrospray ionization (ESI) mode in this mass spectrometry analysis. The standard curve met linear requirements within the concentration range from 3 to 1000 ng/mL, and the lower limit of quantification (LLOQ) was 3 ng/mL. The method was evaluated regarding precision, accuracy, recovery, matrix effect, and stability, and all the results met the criteria presented in the guidelines for validation of biological analysis method. Then the pharmacokinetic profiles of Demethylsinomenine in rat plasma were characterized using this validated UPLC-MS/MS method. Demethylsinomenine exhibited the feature of linear pharmacokinetics after intravenous () or intragastric () administration in rats. After bolus at three dosage levels (0.5, 1, and 2 mg/kg), Demethylsinomenine showed the profiles of rapid elimination with mean half-life (T) of 1.55-1.73 h, and extensive tissue distribution with volume of distribution (V) of 5.62-8.07 L/kg. After administration at three dosage levels (10, 20, and 40 mg/kg), Demethylsinomenine showed the consistent peak time (T) of 3 h and the mean absolute bioavailability of Demethylsinomenine was 30.46%. These pharmacokinetics findings will aid in future drug development decisions of Demethylsinomenine as a potential candidate for pain analgesia.